|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00256880 |
The purpose of this study is to determine how effective and safe a new investigational drug is in treating patients with relapsed or refractory multiple myeloma. The treatment involves daily dosing. A patient may continue to receive the treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times to measure the amount of drug in your body at specific times after the drug is given. Blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment. During the treatment phase, the patients will undergo regular assessments for safety and clinical response.
Condition | Intervention | Phase |
Multiple Myeloma |
Drug: GW786034 |
Phase II |
Genetics Home Reference related topics: | aceruloplasminemia hemophilia |
MedlinePlus related topics: | Cancer Multiple Myeloma |
ChemIDplus related topics: | Pazopanib |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment |
Official Title: | A Phase II, Open-Label Study of Pazopanib (GW786034) in Patients With Relapsed or Refractory Multiple Myeloma |
Enrollment: | 100 |
Study Start Date: | January 2005 |
Ages Eligible for Study: | 21 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion criteria:
United States, Arkansas | |||||
GSK Clinical Trials Call Center | |||||
Little Rock, Arkansas, United States, 72205 | |||||
United States, Massachusetts | |||||
GSK Clinical Trials Call Center | |||||
Boston, Massachusetts, United States, 022115 | |||||
United States, New York | |||||
GSK Clinical Trials Call Center | |||||
New York, New York, United States, 10011-8202 | |||||
United States, North Carolina | |||||
GSK Clinical Trials Call Center | |||||
Durham, North Carolina, United States, 27710 | |||||
United States, Ohio | |||||
GSK Clinical Trials Call Center | |||||
Cleveland, Ohio, United States, 44195 | |||||
United States, Oregon | |||||
GSK Clinical Trials Call Center | |||||
Portland, Oregon, United States, 97239-3098 | |||||
United States, Pennsylvania | |||||
GSK Clinical Trials Call Center | |||||
Philadelphia, Pennsylvania, United States, 19104 | |||||
United States, Washington | |||||
GSK Clinical Trials Call Center | |||||
Seattle, Washington, United States, 98109 | |||||
Australia, Victoria | |||||
GSK Clinical Trials Call Center | |||||
East Melbourne, Victoria, Australia, 3002 | |||||
GSK Clinical Trials Call Center | |||||
Melbourne, Victoria, Australia, 3004 | |||||
GSK Clinical Trials Call Center | |||||
Melbourne, Victoria, Australia, 3052 | |||||
Canada, Alberta | |||||
GSK Clinical Trials Call Center | |||||
Calgary, Alberta, Canada, T2N 4N2 |
GlaxoSmithKline |
Study Director: | GSK Clinical Trials Call Center, MD | GlaxoSmithKline |
Study ID Numbers: | VEG20006 |
First Received: | November 21, 2005 |
Last Updated: | September 12, 2007 |
ClinicalTrials.gov Identifier: | NCT00256880 |
Health Authority: | United States: Food and Drug Administration; Australia: National Health and Medical Research Council |
|
|
|
|